Glecaprevir + Pibrentasvir

Category: Hepatitis

Glecaprevir + Pibrentasvir Overview

Glecaprevir/pibrentasvir (trade name Mavyret in the US and Maviret in Europe) is a combination drug containing glecaprevir (100mg) and pibrentasvir (40mg). In the United States, it was approved by the Food and Drug Administration in August 2017 for treatment of hepatitis C.[1] In Europe, it was also approved in August 2017 for the same indication.[2] In the United States, a treatment course of Mavyret costs about $26,400 before discounts.[3] ...

Read more Glecaprevir + Pibrentasvir Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Glecaprevir + Pibrentasvir Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Glecaprevir + Pibrentasvir
  • Tablet: 100mg + 40mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Drugs with one or more similar ingredients: (1 result)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 18 August 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA